Skip to main content Skip to navigation

Olaparib – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026 Medically reviewed by: RxHarun Orthopedic Specialist Doctor Reading time: 82 min read
Olaparib - Uses, Dosage, Side Effects, Interactions

Olaparib is a small molecule inhibitor of poly ADP-ribose polymerase and is used as an antineoplastic agent in the therapy of refractory and advanced ovarian carcinoma. Olaparib therapy is associated with a low rate of transient elevations in serum aminotransferase during therapy and has not been linked to instances of clinically apparent liver injury.

Olaparib is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single-strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.

Olaparib is a member of the class of N-acyl piperazines obtained by formal condensation of the carboxy group of 2-fluoro-5-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]benzoic acid with the free amino group of N-(cyclpropylcarbonyl)piperazine; used to treat advanced ovarian cancer. It has a role as an antineoplastic agent, an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor, and an apoptosis inducer. It is an N-acyl piperazine, a member of cyclopropanes, a member of monofluorobenzenes, and a member of phthalazines.

Olaparib is used to treat a number of BRCA-associated tumors, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.

Mechanism of Action

Poly(ADP-ribose) polymerases (PARPs) are multifunctional enzymes comprising 17 members. They are involved in essential cellular functions, such as DNA transcription and DNA repair. PARPs recognize and repair cellular DNA damage, such as single-strand breaks (SSBs) and double-strand breaks (DSBs). Different DNA repair pathways exist to repair these DNA damages, including the base excision repair (BER) pathway for SSBs and BRCA-dependent homologous recombination for DSBs. Olaparib is a PARP inhibitor: while it acts on PARP1, PARP2, and PARP3, olaparib is a more selective competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of DSBs, which is the most toxic form of DNA damage. While BRCA-dependent homologous recombination can repair DSBs in normal cells, this repair pathway is defective in cells with BRCA1/2 mutations, such as certain tumor cells. Inhibition of PARP in cancer cells with BRCA mutations leads to genomic instability and apoptotic cell death. This end result is also referred to as synthetic lethality, a phenomenon where the combination of two defects – inhibition of PARP activity and loss of DSB repair by HR – that are otherwise benign when alone, leads to detrimental results. _In vitro_ studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.

Olaparib is a cytotoxic and anti-tumor agent. Olaparib inhibits the growth of selective tumor cell lines _in vitro_ and decreases tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. The drug exerts anti-tumour effects in cell lines and mouse tumor models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In preclinical models of cancer, olaparib demonstrated anti-tumor activity when used alone, in combination with chemotherapeutic agents, or radiotherapy. Olaparib can act as a chemosensitizer to potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents such as alkylating agents and platinum-based drugs. It can also act as a radiosensitizer by preventing PARP-mediated DNA repair.

Indications

  • **Ovarian cancer** – Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib is indicated in combination with [bevacizumab] for the maintenance treatment of adults with an advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
  • **Breast cancer** – Olaparib is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious g_BRCA_m human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious g_BRCA_m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR) positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy. **Pancreatic cancer** Olaparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. **Prostate cancer** Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a hormone agent, such as [enzalutamide] or [abiraterone].
  • * Ovarian cancer – Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability.
  • * Breast cancer – Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with anthracycline and taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
  • * Adenocarcinoma of the pancreas – Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
  • * Prostate cancer – Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
  • Advanced ovarian carcinoma – Olaparib is a small molecule inhibitor of poly ADP-ribose polymerase and is used as an antineoplastic agent in the therapy of refractory and advanced ovarian carcinoma.
  • Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
  • Advanced Epithelial Ovarian Cancer
  • Advanced Fallopian Tube Carcinoma
  • Advanced Primary Peritoneal Carcinoma
  • Early Breast Cancer
  • Metastatic Breast Cancer
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Pancreatic Adenocarcinoma Metastatic
  • Recurrent Epithelial Ovarian Cancer
  • Recurrent Fallopian Tube Cancer
  • Recurrent platinum-sensitive primary peritoneal cancer
  • Maintenance therapy

Use in Cancer

Olaparib is approved to treat:

  • Breast cancer is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. It is used after surgery in adults with:
    • High-risk early-stage breast cancer that has been treated with chemotherapy before or after surgery.
    • Metastatic cancer has been treated with chemotherapy before or after the cancer spread.
  • The ovarian epithelial, fallopian tube, or primary peritoneal cancer. Olaparib is used as maintenance therapy in adults who are having a complete or partial response to platinum chemotherapy. It is used:
    • As the first maintenance therapy in patients with advanced cancer that has certain germline or somatic mutations in the BRCA1 or BRCA2 gene.
    • Bevacizumab as the first maintenance therapy in patients with advanced cancer that has genomic instability and/or certain germline or somatic mutations in the BRCA1 or BRCA2 gene.
    • In patients with recurrent cancer.
  • Pancreatic cancer. Olaparib is used as maintenance therapy in adults with metastatic cancer that has not progressed after first-line therapy with platinum chemotherapy and has certain germline mutations in the BRCA1 or BRCA2 gene.
  • Prostate cancer that is metastatic, has germline or somatic mutations in certain genes involved in the homologous recombination repair pathway, and is castrate-resistant (has not responded to treatments that lower testosterone levels). Olaparib is used in adults whose cancer has gotten worse after treatment with enzalutamide or abiraterone.

Olaparib is also being studied in the treatment of other types of cancer.

Contraindications

  • acute myeloid leukemia, a type of blood cancer
  • a type of inflammation of the lung called interstitial pneumonitis
  • myelodysplastic syndrome, a bone marrow disorder
  • pregnancy
  • a patient who is producing milk and breastfeeding
  • chronic kidney disease stage 3A (moderate)
  • chronic kidney disease stage 3B (moderate)

Dosage

Strengths: 50 mg; 100 mg; 150 mg

Breast Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
  • When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION RESISTANT PROSTATE CANCER:

  • 300 mg orally 2 times a day until disease progression or unacceptable toxicity
  • Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
  • Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
  • Refer to the prescribing Information for bevacizumab when used in combination with this drug for more information.
  • BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
  • FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
  • MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
  • ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
  • GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
  • FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
  • GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Prostate Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
  • When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

  • 300 mg orally 2 times a day until disease progression or unacceptable toxicity
  • Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
  • Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
  • Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
  • BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
  • FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
  • MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
  • ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
  • GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
  • FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
  • GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Ovarian Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
  • When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

  • 300 mg orally 2 times a day until disease progression or unacceptable toxicity
  • Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
  • Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
  • Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
  • BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
  • FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
  • MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
  • ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
  • GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
  • FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
  • GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Fallopian Tube Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 year
  • When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

  • 300 mg orally 2 times a day until disease progression or unacceptable toxicity
  • Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
  • Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
  • Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
  • BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
  • FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
  • MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
  • ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
  • GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy
  • FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
  • GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Peritoneal Cancer

FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years

FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:

  • 300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years
  • When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.

RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:

  • 300 mg orally 2 times a day until disease progression or unacceptable toxicity
  • Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen.
  • Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy.
  • Refer to the prescribing information for bevacizumab when used in combination with this drug for more information.
  • BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy
  • FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability
  • MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with a recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy
  • ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy
  • GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy
  • FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen
  • GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone

Dose Adjustments

  • FIRST DOSE REDUCTION: 250 mg orally 2 times a day
  • SECOND DOSE REDUCTION: 200 mg orally 2 times a day

CYP450 3A inhibitors Avoid concomitant use of this drug with CYP450 3A inhibitors and consider alternative agents. If concomitant use cannot be avoided:

  • Reduce dose to 150 mg orally 2 times a day when used with moderate CYP450 3A inhibitor.
  • Reduce dose to 100 mg orally 2 times a day when used with strong CYP450 3A inhibitor.

Administration advice:

  • This drug may be taken with or without food.
  • The 100-mg tablet is available for dose reduction.
  • Swallow tablets whole; do not chew, crush, dissolve, or divide.
  • Advise patients to avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they may increase the level of this drug in the blood.
  • If a patient misses a dose, instruct them to take their next dose at its scheduled time.

Side Effects

The Most Common

  • nausea
  • vomiting
  • diarrhea
  • constipation
  • heartburn
  • headache
  • decreased appetite
  • muscle, joint, or back pain
  • fatigue
  • dizziness
  • stomach pain or discomfort
  • taste changes
  • mouth pain or sores
  • rash
  • shortness of breath, new or worsening cough, difficulty breathing, wheezing, or fever
  • weakness
  • extreme tiredness
  • weight loss
  • unusual bruising or bleeding
  • pale skin
  • blood in urine or stool
  • fever, chills, cough, sore throat, difficulty urinating, pain when urinating, or other signs of infection
  • pain, tenderness, redness, or swelling in one leg
  • chest pain or tightness; shortness of breath; coughing up blood; or rapid breathing

More common

  • Black, tarry stools
  • bladder pain
  • bleeding gums
  • bloody or cloudy urine
  • body aches or pain
  • chest pain or tightness
  • chills
  • cough
  • cough producing mucus
  • diarrhea
  • difficult, burning, or painful urination
  • ear congestion or pain
  • fast, pounding, or irregular heartbeat or pulse
  • fever
  • frequent urge to urinate
  • general feeling of discomfort or illness
  • head congestion
  • headache
  • hoarseness or other voice changes
  • joint pain
  • loss of appetite
  • loss of voice
  • lower back or side pain
  • muscle aches and pains
  • nausea
  • pain or swelling in the arms or legs
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • rapid shallow breathing
  • runny or stuffy nose
  • shivering
  • sneezing
  • sore throat
  • sores, ulcers, or white spots on the lips or in the mouth
  • sweating
  • swollen glands
  • trouble sleeping
  • trouble breathing
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting

Rare

  • Hives, itching, skin rash
  • irritation
  • joint stiffness or swelling
  • redness of the skin
  • swelling of the eyelids, face, lips, hands, or feet
  • trouble swallowing
  • Back pain
  • belching
  • blistering, crusting, irritation, itching, or reddening of the skin
  • blurred vision
  • burning, numbness, tingling, or painful sensations
  • constipation
  • cracked, dry, or scaly skin
  • decreased appetite
  • diarrhea
  • difficulty with moving
  • dizziness
  • dry mouth
  • fear or nervousness
  • flushed, dry skin
  • fruit-like breath odor
  • heartburn
  • increased hunger
  • increased thirst
  • increased urination
  • indigestion
  • lack or loss of strength
  • loss of bladder control
  • loss of or change in taste
  • muscle stiffness
  • stomach discomfort, upset, or pain
  • swelling or inflammation of the mouth
  • unexplained weight loss
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

Drug Interactions

Pregnancy and Lactation

AU TGA pregnancy category: D
US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and
embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily [see Data]. Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies.

Lactation

No information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.

Why is this medication prescribed?

Olaparib is used alone or in combination with bevacizumab (Avastin) to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib is also used to treat certain types of breast cancer that has spread to other parts of the body and has not improved or has worsened after treatment with other therapies. It is also used to treat certain types of early breast cancer in people who have already been treated with other chemotherapy treatments. Olaparib is also used to treat a certain type of prostate cancer that has spread to other parts of the body, no longer responds to medical or surgical treatments to lower testosterone levels, and has progressed after treatment with enzalutamide (Xtandi) or abiraterone (Yonsa, Zytiga). Olaparib is also used to treat ovarian cancer that has not improved or has worsened after treatment with at least three other therapies. Olaparib is also used to help maintain the response of a certain type of pancreatic cancer that has not spread or progressed after the first chemotherapy treatment. Olaparib is a polyadenosine 5′-diphosphoribose polymerase (PARP) enzyme inhibitor. It works by killing cancer cells.

How should this medicine be used?

Olaparib comes as a tablet to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the tablets whole; do not crush chew, divide, or dissolve them.

Your doctor may decrease your dose of olaparib or tell you to stop taking olaparib for a period of time during your treatment. This will depend on how well the medication works for you and any side effects you may experience. Be sure to tell your doctor how you are feeling during your treatment with olaparib.

Your doctor or pharmacist will give you the manufacturer’s patient information sheet (Medication Guide) when you begin treatment with olaparib. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also visit the Food and Drug Administration (FDA) website (https://www.fda.gov/Drugs/DrugSafety/ucm085729.htm) to obtain the Medication Guide.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking olaparib,

  • tell your doctor and pharmacist if you are allergic to olaparib, any other medications, or any of the ingredients in olaparib tablets. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • The following herbal products may interact with olaparib: St. John’s wort. Be sure to let your doctor and pharmacist know that you are taking this medication before you start taking olaparib. Do not start this medication while taking olaparib without discussing it with your healthcare provider.
  • tell your doctor if you have or have ever had have lung or breathing problems, blood clots in your legs or lungs, or kidney or liver disease.
  • tell your doctor if you are pregnant, plan to become pregnant, or plan to father a child. You may need to have a pregnancy test before starting treatment, You should not become pregnant while you are taking olaparib. You should use effective birth control to prevent pregnancy during your treatment with olaparib and for at least 6 months after your final dose. If you are a male and your partner can become pregnant, you should use effective birth control during your treatment with olaparib tablets and for 3 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you become pregnant while taking olaparib, call your doctor immediately. Olaparib may harm the fetus.
  • tell your doctor if you are breastfeeding. Do not breastfeed while you are taking olaparib and for 1 month after your final dose.
  • you should know that you should not donate sperm while you are taking olaparib tablets and for 3 months after your final dose.

What special dietary instructions should I follow?

Do not eat grapefruit or Seville oranges (sometimes used in marmalades), or drink grapefruit juice or Seville orange juice while taking this medication.

What should I do if I forget a dose?

Skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s013lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf
  4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206162s011lbl.pdf
  5. https://pubchem.ncbi.nlm.nih.gov/compound/Olaparib
  6. https://pubchem.ncbi.nlm.nih.gov/#query=olaparib
  7. https://www.cancer.gov/about-cancer/treatment/drugs/olaparib
  8. https://go.drugbank.com/drugs/DB09074
  9. https://www.drugs.com/mtm/olaparib.html
  10. https://en.wikipedia.org/wiki/Olaparib
  11. https://medlineplus.gov/druginfo/meds/a614060.html
  12. https://www.mayoclinic.org/drugs-supplements/olaparib-oral-route/side-effects/drg-20127672
  13. BindingDB
    https://www.bindingdb.org/rwd/bind/info.jsp
    https://www.bindingdb.org/rwd/bind/chemsearch/marvin/MolStructure.jsp?monomerid=27566
  14. ChEMBL
    http://www.ebi.ac.uk/Information/termsofuse.html
    https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL521686/
    https://www.ebi.ac.uk/chembl/g/#browse/targets
  15. Chemical Probes Portal
    https://www.chemicalprobes.org/olaparib
  16. Comparative Toxicogenomics Database (CTD)
    http://ctdbase.org/about/legal.jsp
    https://ctdbase.org/detail.go?type=chem&acc=C531550
  17. Drug Gene Interaction database (DGIdb)
    http://www.dgidb.org/downloads
    https://www.dgidb.org/drugs/OLAPARIB
  18. IUPHAR/BPS Guide to PHARMACOLOGY
    https://www.guidetopharmacology.org/about.jsp#license
    https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7519
    https://www.guidetopharmacology.org/targets.jsp
  19. Therapeutic Target Database (TTD)
    https://idrblab.net/ttd/data/drug/details/D0J9HW
  20. CAS Common Chemistry
    https://creativecommons.org/licenses/by-nc/4.0/
    https://commonchemistry.cas.org/detail?cas_rn=763113-22-0
  21. ChemIDplus
    https://www.nlm.nih.gov/copyright.html
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0763113220
    https://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
  22. DrugBank
    https://www.drugbank.ca/legal/terms_of_use
    https://www.drugbank.ca/drugs/DB09074
  23. DTP/NCI
    https://www.cancer.gov/policies/copyright-reuse
    https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=747856
  24. European Chemicals Agency (ECHA)
    https://echa.europa.eu/web/guest/legal-notice
    https://echa.europa.eu/information-on-chemicals
    https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/175706
  25. FDA Global Substance Registration System (GSRS)
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://gsrs.ncats.nih.gov/ginas/app/beta/substances/WOH1JD9AR8
  26. ChEBI
    http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:83766
    http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
  27. FDA Pharm Classes
    https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm
    https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm
  28. LiverTox
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/n/livertox/Olaparib/
  29. NCI Thesaurus (NCIt)
    https://www.cancer.gov/policies/copyright-reuse
    https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C71721
    https://ncit.nci.nih.gov
  30. ClinicalTrials.gov
    https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
    https://clinicaltrials.gov/
  31. DailyMed
    https://www.nlm.nih.gov/copyright.html
    https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OLAPARIB
  32. Nature Chemical Biology
    https://pubchem.ncbi.nlm.nih.gov/substance/319530703
  33. European Medicines Agency (EMA)
    https://www.ema.europa.eu/en/about-us/legal-notice
    https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza
  34. Drugs and Lactation Database (LactMed)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/books/NBK500884/
  35. EU Clinical Trials Register
    https://www.clinicaltrialsregister.eu/
  36. FDA Orange Book
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
  37. WHO Anatomical Therapeutic Chemical (ATC) Classification
    https://www.whocc.no/copyright_disclaimer/
    https://www.whocc.no/atc/
    https://www.whocc.no/atc_ddd_index/
  38. FDA Medication Guides
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
  39. National Drug Code (NDC) Directory
    https://www.fda.gov/about-fda/about-website/website-policies#linking
    https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
  40. Human Metabolome Database (HMDB)
    http://www.hmdb.ca/citing
    http://www.hmdb.ca/metabolites/HMDB0255929
  41. Metabolomics Workbench
    https://www.metabolomicsworkbench.org/data/StructureData.php?RegNo=152129
  42. NCI Cancer Drugs
    https://www.cancer.gov/policies/copyright-reuse
    https://www.cancer.gov/about-cancer/treatment/drugs/olaparib
  43. NIPH Clinical Trials Search of Japan
    https://rctportal.niph.go.jp/en/
  44. NLM RxNorm Terminology
    https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html
    https://rxnav.nlm.nih.gov/id/rxnorm/1597582
  45. Protein Data Bank in Europe (PDBe)
    http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/09L
  46. https://pubchem.ncbi.nlm.nih.gov
    https://gitlab.lcsb.uni.lu/eci/pubchem-docs/-/raw/main/pfas-tree/PFAS_Tree.pdf?inline=false
  47. RCSB Protein Data Bank (RCSB PDB)
    https://www.rcsb.org/pages/policies
    https://www.rcsb.org/
  48. Springer Nature
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=32061439-588096928
  49. Thieme Chemistry
    https://creativecommons.org/licenses/by-nc-nd/4.0/
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=32061439-588096928
  50. Wikidata
    https://creativecommons.org/publicdomain/zero/1.0/
    https://www.wikidata.org/wiki/Q7083106
  51. Wiley
    https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=70782
  52. Medical Subject Headings (MeSH)
    https://www.nlm.nih.gov/copyright.html
    https://www.ncbi.nlm.nih.gov/mesh/67531550
    http://www.nlm.nih.gov/mesh/meshhome.html
    https://www.ncbi.nlm.nih.gov/mesh/68000970
    https://www.ncbi.nlm.nih.gov/mesh/2009774
  53. KEGG
    https://www.kegg.jp/kegg/legal.html
    http://www.genome.jp/kegg-bin/get_htext?br08301.keg
    http://www.genome.jp/kegg-bin/get_htext?br08302.keg
    http://www.genome.jp/kegg-bin/get_htext?br08303.keg
    http://www.genome.jp/kegg-bin/get_htext?br08310.keg
    http://www.genome.jp/kegg-bin/get_htext?br08330.keg
    http://www.genome.jp/kegg-bin/get_htext?br08332.keg
  54. UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)
    http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
  55. NORMAN Suspect List Exchange
    https://creativecommons.org/licenses/by/4.0/
    https://www.norman-network.com/nds/SLE/
  56. EPA DSSTox
    https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources
    https://comptox.epa.gov/dashboard/chemical-lists/
  57. PATENTSCOPE (WIPO)
    https://pubchem.ncbi.nlm.nih.gov/substance/390791144
  58. https://www.ncbi.nlm.nih.gov/projects/linkout

 

g

Frequently Asked Questions

Mechanism of ActionPoly(ADP-ribose) polymerases (PARPs) are multifunctional enzymes comprising 17 members. They are involved in essential cellular functions, such as DNA transcription and DNA repair. PARPs recognize and repair cellular DNA damage, such as single-strand breaks (SSBs) and double-strand breaks (DSBs). Different DNA repair pathways exist to repair these DNA damages, including the base excision repair (BER) pathway for SSBs and BRCA-dependent homologous recombination for DSBs. Olaparib is a PARP inhibitor: while it acts on PARP1, PARP2, and PARP3, olaparib is a more selective competitive inhibitor of NAD+ at the catalytic site of PARP1 and PARP2. Inhibition of the BER pathway by olaparib leads to the accumulation of unrepaired SSBs, which leads to the formation of DSBs, which is the most toxic form of DNA damage. While BRCA-dependent homologous recombination can repair DSBs in normal cells, this repair pathway is defective in cells with BRCA1/2 mutations, such as certain tumor cells. Inhibition of PARP in cancer cells with BRCA mutations leads to genomic instability and apoptotic cell death. This end result is also referred to as synthetic lethality, a phenomenon where the combination of two defects - inhibition of PARP activity and loss of DSB repair by HR - that are otherwise benign when alone, leads to detrimental results. _In vitro_ studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage and cancer cell death.Olaparib is a cytotoxic and anti-tumor agent. Olaparib inhibits the growth of selective tumor cell lines _in vitro_ and decreases tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. The drug exerts anti-tumour effects in cell lines and mouse tumor models with deficiencies in BRCA1/2, ATM, or other genes involved in the homologous recombination repair (HRR) of DNA damage and correlated with platinum response. In preclinical models of cancer, olaparib demonstrated anti-tumor activity when used alone, in combination with chemotherapeutic agents, or radiotherapy. Olaparib can act as a chemosensitizer to potentiate the cytotoxicity of DNA-damaging chemotherapeutic agents such as alkylating agents and platinum-based drugs. It can also act as a radiosensitizer by preventing PARP-mediated DNA repair.Indications**Ovarian cancer** - Olaparib is indicated for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Olaparib is indicated in combination with [bevacizumab] for the maintenance treatment of adults with an advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. **Breast cancer** - Olaparib is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious g_BRCA_m human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious g_BRCA_m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR) positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy. **Pancreatic cancer** Olaparib is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. **Prostate cancer** Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a hormone agent, such as [enzalutamide] or [abiraterone]. * Ovarian cancer - Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy maintenance treatment of adult patients with platinum-sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. Lynparza in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. * Breast cancer - Lynparza is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with anthracycline and taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. * Adenocarcinoma of the pancreas - Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. * Prostate cancer - Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA mutated (germline and/or somatic) high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy. Advanced ovarian carcinoma - Olaparib is a small molecule inhibitor of poly ADP-ribose polymerase and is used as an antineoplastic agent in the therapy of refractory and advanced ovarian carcinoma. Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. Advanced Epithelial Ovarian Cancer Advanced Fallopian Tube Carcinoma Advanced Primary Peritoneal Carcinoma Early Breast Cancer Metastatic Breast Cancer Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pancreatic Adenocarcinoma Metastatic Recurrent Epithelial Ovarian Cancer Recurrent Fallopian Tube Cancer Recurrent platinum-sensitive primary peritoneal cancer Maintenance therapyUse in Cancer Olaparib is approved to treat:Breast cancer is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. It is used after surgery in adults with:High-risk early-stage breast cancer that has been treated with chemotherapy before or after surgery. Metastatic cancer has been treated with chemotherapy before or after the cancer spread.The ovarian epithelial, fallopian tube, or primary peritoneal cancer. Olaparib is used as maintenance therapy in adults who are having a complete or partial response to platinum chemotherapy. It is used:As the first maintenance therapy in patients with advanced cancer that has certain germline or somatic mutations in the BRCA1 or BRCA2 gene. Bevacizumab as the first maintenance therapy in patients with advanced cancer that has genomic instability and/or certain germline or somatic mutations in the BRCA1 or BRCA2 gene. In patients with recurrent cancer.Pancreatic cancer. Olaparib is used as maintenance therapy in adults with metastatic cancer that has not progressed after first-line therapy with platinum chemotherapy and has certain germline mutations in the BRCA1 or BRCA2 gene. Prostate cancer that is metastatic, has germline or somatic mutations in certain genes involved in the homologous recombination repair pathway, and is castrate-resistant (has not responded to treatments that lower testosterone levels). Olaparib is used in adults whose cancer has gotten worse after treatment with enzalutamide or abiraterone.Olaparib is also being studied in the treatment of other types of cancer.Contraindicationsacute myeloid leukemia, a type of blood cancer a type of inflammation of the lung called interstitial pneumonitis myelodysplastic syndrome, a bone marrow disorder pregnancy a patient who is producing milk and breastfeeding chronic kidney disease stage 3A (moderate) chronic kidney disease stage 3B (moderate)Dosage Strengths: 50 mg; 100 mg; 150 mg Breast Cancer FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 yearsFIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION RESISTANT PROSTATE CANCER:300 mg orally 2 times a day until disease progression or unacceptable toxicity Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy. Refer to the prescribing Information for bevacizumab when used in combination with this drug for more information. BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abirateroneProstate Cancer FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 yearsFIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:300 mg orally 2 times a day until disease progression or unacceptable toxicity Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy. Refer to the prescribing information for bevacizumab when used in combination with this drug for more information. BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abirateroneOvarian Cancer FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 yearsFIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:300 mg orally 2 times a day until disease progression or unacceptable toxicity Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy. Refer to the prescribing information for bevacizumab when used in combination with this drug for more information. BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abirateroneFallopian Tube Cancer FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 yearsFIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 year When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:300 mg orally 2 times a day until disease progression or unacceptable toxicity Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy. Refer to the prescribing information for bevacizumab when used in combination with this drug for more information. BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abirateronePeritoneal Cancer FIRST-LINE MAINTENANCE TREATMENT OF BRCA-MUTATED ADVANCED OVARIAN CANCER:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 yearsFIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB:300 mg orally 2 times a day until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop; patients with evidence of disease at 2 years, who in the opinion of the treating healthcare provider can derive further benefit from therapy, can be treated beyond 2 years When used with this drug, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks for a total of 15 months including the period given with chemotherapy and given as maintenance.RECURRENT OVARIAN CANCER; GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER; HER2-NEGATIVE METASTATIC BREAST CANCER; METASTATIC PANCREATIC ADENOCARCINOMA; HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER:300 mg orally 2 times a day until disease progression or unacceptable toxicity Patients should start therapy no later than 8 weeks after completion of their final dose of the platinum-containing regimen. Patients should have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumor) before initiation of therapy. Refer to the prescribing information for bevacizumab when used in combination with this drug for more information. BRCA-MUTATED ADVANCED OVARIAN CANCER: For maintenance therapy of patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy FIRST-LINE MAINTENANCE TREATMENT OF HRD-POSITIVE ADVANCED OVARIAN CANCER IN COMBINATION WITH BEVACIZUMAB: In combination with bevacizumab for the maintenance treatment of adult patients with an advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a deleterious or suspected deleterious BRCA mutation AND/OR genomic instability MAINTENANCE TREATMENT OF RECURRENT OVARIAN CANCER: For the maintenance treatment of patients with a recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy ADVANCED GERMLINE BRCA-MUTATED OVARIAN CANCER AFTER 3 OR MORE LINES OF CHEMOTHERAPY: For the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER: For the treatment of patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with prior endocrine therapy or be considered inappropriate for endocrine therapy FIRST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA: For maintenance treatment of patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: For treatment of patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abirateroneDose AdjustmentsFIRST DOSE REDUCTION: 250 mg orally 2 times a day SECOND DOSE REDUCTION: 200 mg orally 2 times a dayCYP450 3A inhibitors Avoid concomitant use of this drug with CYP450 3A inhibitors and consider alternative agents. If concomitant use cannot be avoided:Reduce dose to 150 mg orally 2 times a day when used with moderate CYP450 3A inhibitor. Reduce dose to 100 mg orally 2 times a day when used with strong CYP450 3A inhibitor.Administration advice:This drug may be taken with or without food. The 100-mg tablet is available for dose reduction. Swallow tablets whole; do not chew, crush, dissolve, or divide. Advise patients to avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they may increase the level of this drug in the blood. If a patient misses a dose, instruct them to take their next dose at its scheduled time.Side Effects The Most Commonnausea vomiting diarrhea constipation heartburn headache decreased appetite muscle, joint, or back pain fatigue dizziness stomach pain or discomfort taste changes mouth pain or sores rash shortness of breath, new or worsening cough, difficulty breathing, wheezing, or fever weakness extreme tiredness weight loss unusual bruising or bleeding pale skin blood in urine or stool fever, chills, cough, sore throat, difficulty urinating, pain when urinating, or other signs of infection pain, tenderness, redness, or swelling in one leg chest pain or tightness; shortness of breath; coughing up blood; or rapid breathingMore commonBlack, tarry stools bladder pain bleeding gums bloody or cloudy urine body aches or pain chest pain or tightness chills cough cough producing mucus diarrhea difficult, burning, or painful urination ear congestion or pain fast, pounding, or irregular heartbeat or pulse fever frequent urge to urinate general feeling of discomfort or illness head congestion headache hoarseness or other voice changes joint pain loss of appetite loss of voice lower back or side pain muscle aches and pains nausea pain or swelling in the arms or legs painful or difficult urination pale skin pinpoint red spots on the skin rapid shallow breathing runny or stuffy nose shivering sneezing sore throat sores, ulcers, or white spots on the lips or in the mouth sweating swollen glands trouble sleeping trouble breathing unusual bleeding or bruising unusual tiredness or weakness vomitingRareHives, itching, skin rash irritation joint stiffness or swelling redness of the skin swelling of the eyelids, face, lips, hands, or feet trouble swallowing Back pain belching blistering, crusting, irritation, itching, or reddening of the skin blurred vision burning, numbness, tingling, or painful sensations constipation cracked, dry, or scaly skin decreased appetite diarrhea difficulty with moving dizziness dry mouth fear or nervousness flushed, dry skin fruit-like breath odor heartburn increased hunger increased thirst increased urination indigestion lack or loss of strength loss of bladder control loss of or change in taste muscle stiffness stomach discomfort, upset, or pain swelling or inflammation of the mouth unexplained weight loss unsteadiness or awkwardness weakness in the arms, hands, legs, or feetDrug InteractionsDRUG INTERACTIONAbametapir The serum concentration of Olaparib can be increased when it is combined with Abametapir.Abatacept The metabolism of Olaparib can be increased when combined with Abatacept.Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Olaparib.Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Olaparib.Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Olaparib.Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Olaparib.Acetaminophen The metabolism of Olaparib can be increased when combined with Acetaminophen.Acetazolamide The metabolism of Olaparib can be decreased when combined with Acetazolamide.Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Olaparib.Adalimumab The metabolism of Olaparib can be increased when combined with Adalimumab.Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Olaparib.Albendazole The metabolism of Olaparib can be decreased when combined with Albendazole.Aldesleukin The metabolism of Olaparib can be decreased when combined with Aldesleukin.Alectinib The metabolism of Alectinib can be decreased when combined with Olaparib.Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Olaparib.Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olaparib.Alfentanil The metabolism of Olaparib can be decreased when combined with Alfentanil.Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Olaparib.Allogeneic process The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Olaparib.Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Olaparib.Alpelisib The metabolism of Olaparib can be increased when combined with Alpelisib.Alprazolam The metabolism of Alprazolam can be decreased when combined with Olaparib.Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Olaparib.Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Olaparib.Ambrisentan The metabolism of Olaparib can be decreased when combined with Ambrisentan.Aminoglutethimide The metabolism of Olaparib can be increased when combined with Aminoglutethimide.Aminophylline The metabolism of Aminophylline can be decreased when combined with Olaparib.Amiodarone The metabolism of Olaparib can be decreased when combined with Amiodarone.Amitriptyline The metabolism of Olaparib can be decreased when combined with Amitriptyline.Amobarbital The metabolism of Olaparib can be increased when combined with Amobarbital.Amprenavir The metabolism of Olaparib can be decreased when combined with Amprenavir.Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Olaparib.Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Olaparib.Anakinra The metabolism of Olaparib can be increased when combined with Anakinra.Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Olaparib.Anifrolumab The risk or severity of adverse effects can be increased when Olaparib is combined with Anifrolumab.Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Olaparib.Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Olaparib.Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Olaparib.Antilymphocyte The risk or severity of adverse effects can be increased when Olaparib is combined with Antilymphocyte immunoglobulin (horse).Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Olaparib.Antithrombin III The risk or severity of bleeding can be increased when Antithrombin III human is combined with Olaparib.Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olaparib.Apalutamide The metabolism of Olaparib can be increased when combined with Apalutamide.Apixaban The metabolism of Olaparib can be decreased when combined with Apixaban.Apomorphine The metabolism of Olaparib can be decreased when combined with Apomorphine.Apremilast The metabolism of Olaparib can be increased when combined with Apremilast.Aprepitant The metabolism of Olaparib can be decreased when combined with Aprepitant.Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Olaparib.Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Olaparib.Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Olaparib.Aripiprazole la The metabolism of Aripiprazole lauroxil can be decreased when combined with Olaparib.Armodafinil The metabolism of Olaparib can be increased when combined with Armodafinil.Arsenic trioxide The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Olaparib.Artemether The metabolism of Olaparib can be decreased when combined with Artemether.Articaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Articaine.Asciminib The serum concentration of Olaparib can be increased when it is combined with Asciminib.Astemizole The metabolism of Astemizole can be decreased when combined with Olaparib.AstraZeneca COVID The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Olaparib.Asunaprevir The metabolism of Olaparib can be increased when combined with Asunaprevir.Atazanavir The metabolism of Olaparib can be decreased when combined with Atazanavir.Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Olaparib.Avacopan The metabolism of Olaparib can be decreased when combined with Avacopan.Avanafil The serum concentration of Avanafil can be increased when it is combined with Olaparib.Axitinib The metabolism of Axitinib can be decreased when combined with Olaparib.Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Olaparib.Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Olaparib.Azelastine The metabolism of Olaparib can be decreased when combined with Azelastine.Azithromycin The metabolism of Olaparib can be decreased when combined with Azithromycin.Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Olaparib.Bacillus calmette The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Olaparib.Bacillus cal The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Olaparib.Baricitinib The risk or severity of adverse effects can be increased when Olaparib is combined with Baricitinib.Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Olaparib.BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Olaparib.Beclomethasone d The metabolism of Olaparib can be increased when combined with Beclomethasone dipropionate.Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Olaparib.Belimumab The risk or severity of adverse effects can be increased when Belimumab is combined with Olaparib.Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Olaparib.Belumosudil The risk or severity of adverse effects can be increased when Olaparib is combined with Belumosudil.Belzutifan The serum concentration of Olaparib can be decreased when it is combined with Belzutifan.Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Olaparib.Bendamustine The risk or severity of adverse effects can be increased when Bendamustine is combined with Olaparib.Bendroflumet The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Olaparib.Benzocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Benzocaine.Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Olaparib.Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Benzyl alcohol.Berotralstat The metabolism of Olaparib can be decreased when combined with Berotralstat.Betamethasone The metabolism of Olaparib can be increased when combined with Betamethasone.Betamethasone p The metabolism of Olaparib can be increased when combined with Betamethasone phosphate.Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Olaparib.Bexarotene The metabolism of Olaparib can be increased when combined with Bexarotene.Bicalutamide The metabolism of Olaparib can be decreased when combined with Bicalutamide.Bifonazole The metabolism of Olaparib can be decreased when combined with Bifonazole.Bimekizumab The metabolism of Olaparib can be increased when combined with Bimekizumab.Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Olaparib.Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Olaparib.Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Olaparib.Boceprevir The metabolism of Olaparib can be decreased when combined with Boceprevir.Bortezomib The metabolism of Bortezomib can be decreased when combined with Olaparib.Bosentan The metabolism of Olaparib can be increased when combined with Bosentan.Bosutinib The metabolism of Bosutinib can be decreased when combined with Olaparib.Brentuximab ve The metabolism of Brentuximab vedotin can be decreased when combined with Olaparib.Brigatinib The metabolism of Brigatinib can be decreased when combined with Olaparib.Brodalumab The risk or severity of adverse effects can be increased when Olaparib is combined with Brodalumab.Budesonide The metabolism of Olaparib can be increased when combined with Budesonide.Bupivacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Bupivacaine.Buprenorphine The metabolism of Olaparib can be decreased when combined with Buprenorphine.Buspirone The metabolism of Olaparib can be decreased when combined with Buspirone.Busulfan The metabolism of Busulfan can be decreased when combined with Olaparib.Butacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Butacaine.Butalbital The metabolism of Olaparib can be increased when combined with Butalbital.Butamben The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Butamben.Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Olaparib.Cabergoline The metabolism of Cabergoline can be decreased when combined with Olaparib.Calcitriol The metabolism of Olaparib can be increased when combined with Calcitriol.Canakinumab The metabolism of Olaparib can be increased when combined with Canakinumab.Candicidin The metabolism of Olaparib can be decreased when combined with Candicidin.Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Olaparib.Cannabidiol The metabolism of Olaparib can be decreased when combined with Cannabidiol.Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Olaparib.Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Olaparib.Capsaicin The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Capsaicin.Carbamazepine The metabolism of Olaparib can be increased when combined with Carbamazepine.Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Olaparib.Carfilzomib The risk or severity of adverse effects can be increased when Carfilzomib is combined with Olaparib.Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Olaparib.Cefradine The metabolism of Olaparib can be increased when combined with Cefradine.Cenobamate The serum concentration of Olaparib can be decreased when it is combined with Cenobamate.Cephalexin The metabolism of Olaparib can be decreased when combined with Cephalexin.Ceritinib The metabolism of Olaparib can be decreased when combined with Ceritinib.Cerivastatin The metabolism of Olaparib can be increased when combined with Cerivastatin.Certolizumab pegol The metabolism of Olaparib can be increased when combined with Certolizumab pegol.Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Olaparib.Chloramphenicol The metabolism of Olaparib can be decreased when combined with Chloramphenicol.Chloroprocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Chloroprocaine.Chloroquine The metabolism of Olaparib can be decreased when combined with Chloroquine.Chlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Olaparib.Chlorpheniramine The metabolism of Olaparib can be decreased when combined with Chlorpheniramine.Chlorpromazine The metabolism of Olaparib can be increased when combined with Chlorpromazine.Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Olaparib.Cilostazol The metabolism of Cilostazol can be decreased when combined with Olaparib.Cimetidine The metabolism of Olaparib can be decreased when combined with Cimetidine.Cinchocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Cinchocaine.Ciprofloxacin The metabolism of Olaparib can be decreased when combined with Ciprofloxacin.Cisapride The metabolism of Olaparib can be decreased when combined with Cisapride.Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Olaparib.Citalopram The metabolism of Olaparib can be decreased when combined with Citalopram.Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Olaparib.Clarithromycin The metabolism of Olaparib can be decreased when combined with Clarithromycin.Clevidipine The metabolism of Olaparib can be increased when combined with Clevidipine.Clindamycin The metabolism of Olaparib can be decreased when combined with Clindamycin.Clobazam The metabolism of Olaparib can be increased when combined with Clobazam.Clobetasol pro The metabolism of Olaparib can be increased when combined with Clobetasol propionate.Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Olaparib.Clofazimine The metabolism of Olaparib can be decreased when combined with Clofazimine.Clofibrate The metabolism of Olaparib can be increased when combined with Clofibrate.Clomipramine The metabolism of Clomipramine can be decreased when combined with Olaparib.Clonidine The metabolism of Clonidine can be decreased when combined with Olaparib.Clopidogrel The metabolism of Olaparib can be decreased when combined with Clopidogrel.Clostridium t The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.Clozapine The metabolism of Olaparib can be decreased when combined with Clozapine.Cobicistat The metabolism of Olaparib can be decreased when combined with Cobicistat.Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Olaparib.Cocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Cocaine.Colchicine The metabolism of Colchicine can be decreased when combined with Olaparib.Conivaptan The metabolism of Olaparib can be decreased when combined with Conivaptan.Copanlisib The metabolism of Copanlisib can be decreased when combined with Olaparib.Corticotropin The metabolism of Olaparib can be increased when combined with Corticotropin.Cortisone acetate The metabolism of Olaparib can be increased when combined with Cortisone acetate.Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.Crizotinib The metabolism of Olaparib can be decreased when combined with Crizotinib.Curcumin The metabolism of Olaparib can be decreased when combined with Curcumin.Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Olaparib.Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Olaparib.Cyclophosphamide The metabolism of Olaparib can be increased when combined with Cyclophosphamide.Cyclosporine Olaparib may increase the immunosuppressive activities of Cyclosporine.Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Olaparib.Cyproterone acetate The metabolism of Olaparib can be decreased when combined with Cyproterone acetate.Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Olaparib.Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Olaparib.Dabigatran etexilate The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Olaparib.Dabrafenib The serum concentration of Olaparib can be decreased when it is combined with Dabrafenib.Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Olaparib.Daclatasvir The metabolism of Olaparib can be decreased when combined with Daclatasvir.Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Olaparib.Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Olaparib.Dalfopristin The metabolism of Olaparib can be decreased when combined with Dalfopristin.Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Olaparib.Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Olaparib.Danazol The metabolism of Olaparib can be decreased when combined with Danazol.Dapsone The metabolism of Olaparib can be decreased when combined with Dapsone.Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Olaparib.Darunavir The serum concentration of Olaparib can be increased when it is combined with Darunavir.Dasatinib The metabolism of Olaparib can be decreased when combined with Dasatinib.Daunorubicin The metabolism of Olaparib can be decreased when combined with Daunorubicin.Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Olaparib.Deferasirox The metabolism of Olaparib can be increased when combined with Deferasirox.Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Olaparib.Deflazacort The metabolism of Olaparib can be increased when combined with Deflazacort.Delavirdine The metabolism of Olaparib can be decreased when combined with Delavirdine.Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Olaparib.Desipramine The metabolism of Olaparib can be decreased when combined with Desipramine.Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Olaparib.Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Olaparib.Desvenlafaxine The metabolism of Olaparib can be decreased when combined with Desvenlafaxine.Deucravacitinib The risk or severity of adverse effects can be increased when Olaparib is combined with Deucravacitinib.Deutetrabenazine The metabolism of Olaparib can be decreased when combined with Deutetrabenazine.Dexamethasone The metabolism of Olaparib can be increased when combined with Dexamethasone.Dexamethasone ac The metabolism of Olaparib can be increased when combined with Dexamethasone acetate.Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Olaparib.Dextran The risk or severity of bleeding can be increased when Dextran is combined with Olaparib.Dextromethorphan The metabolism of Olaparib can be decreased when combined with Dextromethorphan.Dextropropoxyph The metabolism of Olaparib can be decreased when combined with Dextropropoxyphene.Diazepam The metabolism of Olaparib can be decreased when combined with Diazepam.Dicloxacillin The metabolism of Olaparib can be increased when combined with Dicloxacillin.Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Olaparib.Diethylstilbestrol The metabolism of Olaparib can be decreased when combined with Diethylstilbestrol.Difluocortolone The metabolism of Olaparib can be increased when combined with Difluocortolone.Digitoxin The metabolism of Digitoxin can be decreased when combined with Olaparib.Dihydroergocornine The metabolism of Olaparib can be decreased when combined with Dihydroergocornine.Dihydroergocristine The metabolism of Olaparib can be decreased when combined with Dihydroergocristine.Dihydroergotamine The metabolism of Dihydroergotamine can be decreased when combined with Olaparib.Diltiazem The metabolism of Olaparib can be decreased when combined with Diltiazem.Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Olaparib.Dimethyl sulfoxide The metabolism of Olaparib can be decreased when combined with Dimethyl sulfoxide.Dinutuximab The risk or severity of adverse effects can be increased when Olaparib is combined with Dinutuximab.Diosmin The metabolism of Olaparib can be decreased when combined with Diosmin.Diphenhydramine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Diphenhydramine.Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Olaparib.Diroximel fumarate The risk or severity of adverse effects can be increased when Olaparib is combined with Diroximel fumarate.Disulfiram The metabolism of Olaparib can be decreased when combined with Disulfiram.Docetaxel The metabolism of Docetaxel can be decreased when combined with Olaparib.Dofetilide The metabolism of Dofetilide can be decreased when combined with Olaparib.Domperidone The metabolism of Olaparib can be decreased when combined with Domperidone.Doravirine The metabolism of Olaparib can be decreased when combined with Doravirine.Doxazosin The metabolism of Olaparib can be decreased when combined with Doxazosin.Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Olaparib.Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Olaparib.Dronedarone The metabolism of Olaparib can be decreased when combined with Dronedarone.Drospirenone The metabolism of Olaparib can be decreased when combined with Drospirenone.Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Olaparib.Dutasteride The metabolism of Olaparib can be decreased when combined with Dutasteride.Duvelisib The metabolism of Olaparib can be decreased when combined with Duvelisib.Dyclonine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Dyclonine.Ebastine The metabolism of Olaparib can be decreased when combined with Ebastine.Ebola Zaire vacci The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Olaparib.Echinacea The metabolism of Olaparib can be increased when combined with Echinacea.Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Olaparib.Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Olaparib.Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Olaparib.Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Olaparib.Efavirenz The metabolism of Olaparib can be increased when combined with Efavirenz.Elbasvir The metabolism of Olaparib can be decreased when combined with Elbasvir.Elexacaftor The metabolism of Olaparib can be decreased when combined with Elexacaftor.Eliglustat The metabolism of Eliglustat can be decreased when combined with Olaparib.Elvitegravir The metabolism of Olaparib can be decreased when combined with Elvitegravir.Emapalumab The metabolism of Olaparib can be increased when combined with Emapalumab.Enasidenib The metabolism of Olaparib can be increased when combined with Enasidenib.Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Olaparib.Entrectinib The metabolism of Entrectinib can be decreased when combined with Olaparib.Enzalutamide The metabolism of Olaparib can be increased when combined with Enzalutamide.Epinephrine The metabolism of Olaparib can be decreased when combined with Epinephrine.Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Olaparib.Eplerenone The metabolism of Olaparib can be decreased when combined with Eplerenone.Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Olaparib.Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Olaparib.Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Olaparib.Ergotamine The metabolism of Olaparib can be decreased when combined with Ergotamine.Eribulin The risk or severity of adverse effects can be increased when Eribulin is combined with Olaparib.Erlotinib The metabolism of Erlotinib can be decreased when combined with Olaparib.Erythromycin The metabolism of Olaparib can be decreased when combined with Erythromycin.Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Olaparib.Esketamine The metabolism of Olaparib can be increased when combined with Esketamine.Eslicarbazepine The metabolism of Olaparib can be increased when combined with Eslicarbazepine.Eslicarbazepine ac The metabolism of Olaparib can be increased when combined with Eslicarbazepine acetate.Estetrol The metabolism of Olaparib can be decreased when combined with Estetrol.Estradiol The metabolism of Olaparib can be decreased when combined with Estradiol.Estradiol acetate The metabolism of Olaparib can be increased when combined with Estradiol acetate.Estradiol benzoate The metabolism of Olaparib can be increased when combined with Estradiol benzoate.Estradiol cypionate The metabolism of Olaparib can be increased when combined with Estradiol cypionate.Estradiol dienanthate The metabolism of Olaparib can be increased when combined with Estradiol dienanthate.Estradiol valerate The metabolism of Olaparib can be increased when combined with Estradiol valerate.Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Olaparib.Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Olaparib.Etanercept The metabolism of Olaparib can be increased when combined with Etanercept.Ethambutol The metabolism of Olaparib can be decreased when combined with Ethambutol.Ethanol The metabolism of Olaparib can be increased when combined with Ethanol.Ethinylestradiol The metabolism of Olaparib can be decreased when combined with Ethinylestradiol.Ethyl chloride The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Ethyl chloride.Etidocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Etidocaine.Etoposide The metabolism of Etoposide can be decreased when combined with Olaparib.Etoricoxib The metabolism of Olaparib can be decreased when combined with Etoricoxib.Etravirine The metabolism of Olaparib can be increased when combined with Etravirine.Everolimus The metabolism of Everolimus can be decreased when combined with Olaparib.Famtozinameran The therapeutic efficacy of Famtozinameran can be decreased when used in combination with Olaparib.Felbamate The metabolism of Olaparib can be increased when combined with Felbamate.Felodipine The metabolism of Olaparib can be decreased when combined with Felodipine.Fenofibrate The metabolism of Olaparib can be decreased when combined with Fenofibrate.Fexinidazole The metabolism of Olaparib can be decreased when combined with Fexinidazole.Filgotinib The risk or severity of adverse effects can be increased when Olaparib is combined with Filgotinib.Finasteride The metabolism of Olaparib can be decreased when combined with Finasteride.Finerenone The serum concentration of Finerenone can be increased when it is combined with Olaparib.Fingolimod Olaparib may increase the immunosuppressive activities of Fingolimod.Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Olaparib.Flucloxacillin The metabolism of Olaparib can be increased when combined with Flucloxacillin.Fluconazole The metabolism of Olaparib can be decreased when combined with Fluconazole.Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Olaparib.Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Olaparib.Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Olaparib.Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Olaparib.Flunisolide The metabolism of Olaparib can be increased when combined with Flunisolide.Fluocinolone ac The metabolism of Olaparib can be increased when combined with Fluocinolone acetonide.Fluocinonide The metabolism of Olaparib can be increased when combined with Fluocinonide.Fluocortolone The metabolism of Olaparib can be increased when combined with Fluocortolone.Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Olaparib.Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Olaparib.Fluoxetine The metabolism of Olaparib can be decreased when combined with Fluoxetine.Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Olaparib.Fluprednisolone The risk or severity of adverse effects can be increased when Olaparib is combined with Fluprednisolone.Flutamide The metabolism of Olaparib can be decreased when combined with Flutamide.Fluticasone The metabolism of Olaparib can be increased when combined with Fluticasone.Fluticasone furoate The metabolism of Olaparib can be decreased when combined with Fluticasone furoate.Fluticasone prop The metabolism of Olaparib can be decreased when combined with Fluticasone propionate.Fluvastatin The metabolism of Olaparib can be decreased when combined with Fluvastatin.Fluvoxamine The metabolism of Olaparib can be decreased when combined with Fluvoxamine.Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Olaparib.Formestane The metabolism of Olaparib can be increased when combined with Formestane.Fosamprenavir The metabolism of Olaparib can be decreased when combined with Fosamprenavir.Fosaprepitant The metabolism of Olaparib can be increased when combined with Fosaprepitant.Fosnetupitant The metabolism of Olaparib can be decreased when combined with Fosnetupitant.Fosphenytoin The metabolism of Olaparib can be increased when combined with Fosphenytoin.Fostamatinib The metabolism of Olaparib can be decreased when combined with Fostamatinib.Fusidic acid The metabolism of Olaparib can be decreased when combined with Fusidic acid.Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Olaparib.Gefitinib The metabolism of Olaparib can be decreased when combined with Gefitinib.Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Olaparib.Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olaparib.Gilteritinib The metabolism of Olaparib can be decreased when combined with Gilteritinib.Ginkgo biloba The metabolism of Olaparib can be decreased when combined with Ginkgo biloba.Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Olaparib.Glecaprevir The metabolism of Olaparib can be decreased when combined with Glecaprevir.Glyburide The metabolism of Olaparib can be decreased when combined with Glyburide.Glycerol pheny The metabolism of Olaparib can be increased when combined with Glycerol phenylbutyrate.Golimumab The metabolism of Olaparib can be increased when combined with Golimumab.Griseofulvin The metabolism of Olaparib can be increased when combined with Griseofulvin.Guselkumab The risk or severity of adverse effects can be increased when Olaparib is combined with Guselkumab.Haemophilus The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Olaparib.Halofantrine The metabolism of Olaparib can be decreased when combined with Halofantrine.Haloperidol The metabolism of Olaparib can be decreased when combined with Haloperidol.Heparin The risk or severity of bleeding can be increased when Heparin is combined with Olaparib.Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Olaparib.Hepatitis B Vacci The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Olaparib.Human adenoviru The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Olaparib.Hydralazine The metabolism of Olaparib can be decreased when combined with Hydralazine.Hydrochlorothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Olaparib.Hydrocortamate The metabolism of Olaparib can be increased when combined with Hydrocortamate.Hydrocortisone The metabolism of Olaparib can be increased when combined with Hydrocortisone.Hydrocortisone acet The metabolism of Olaparib can be increased when combined with Hydrocortisone acetate.Hydrocortisone but The metabolism of Olaparib can be increased when combined with Hydrocortisone butyrate.Hydrocortisone cyp The metabolism of Olaparib can be decreased when combined with Hydrocortisone cypionate.Hydrocortisone phos The metabolism of Olaparib can be decreased when combined with Hydrocortisone phosphate.Hydrocortisone succ The metabolism of Olaparib can be increased when combined with Hydrocortisone succinate.Hydroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Olaparib.Hydroxychloroquine The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Olaparib.Hydroxyprogesterone The metabolism of Olaparib can be decreased when combined with Hydroxyprogesterone caproate.Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Olaparib.Hydroxyzine The metabolism of Olaparib can be decreased when combined with Hydroxyzine.Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olaparib.Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Olaparib.Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Olaparib.Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Olaparib.Idelalisib The metabolism of Idelalisib can be decreased when combined with Olaparib.Ifosfamide The metabolism of Olaparib can be increased when combined with Ifosfamide.Iloperidone The metabolism of Iloperidone can be decreased when combined with Olaparib.Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Olaparib.Imatinib The serum concentration of Olaparib can be increased when it is combined with Imatinib.Indinavir The metabolism of Olaparib can be decreased when combined with Indinavir.Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Olaparib.Inebilizumab The risk or severity of infection can be increased when Olaparib is combined with Inebilizumab.Infigratinib The metabolism of Olaparib can be decreased when combined with Infigratinib.Infliximab The metabolism of Olaparib can be increased when combined with Infliximab.Irbesartan The metabolism of Olaparib can be decreased when combined with Irbesartan.Irinotecan The metabolism of Irinotecan can be decreased when combined with Olaparib.Isavuconazole The metabolism of Olaparib can be decreased when combined with Isavuconazole.Isavuconazonium The metabolism of Olaparib can be decreased when combined with Isavuconazonium.Isoniazid The metabolism of Olaparib can be decreased when combined with Isoniazid.Isradipine The metabolism of Olaparib can be decreased when combined with Isradipine.Istradefylline The metabolism of Olaparib can be decreased when combined with Istradefylline.Itraconazole The metabolism of Olaparib can be decreased when combined with Itraconazole.Ivacaftor The metabolism of Olaparib can be decreased when combined with Ivacaftor.Ivosidenib The metabolism of Olaparib can be increased when combined with Ivosidenib.Ixabepilone The metabolism of Ixabepilone can be decreased when combined with Olaparib.Ixazomib The metabolism of Ixazomib can be decreased when combined with Olaparib.Ixekizumab The risk or severity of adverse effects can be increased when Olaparib is combined with Ixekizumab.Janssen COVID-19 The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Olaparib.Jap encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Olaparib.Ketazolam The metabolism of Olaparib can be decreased when combined with Ketazolam.Ketoconazole The metabolism of Olaparib can be decreased when combined with Ketoconazole.Lacosamide The metabolism of Olaparib can be decreased when combined with Lacosamide.Lanreotide The metabolism of Olaparib can be decreased when combined with Lanreotide.Lapatinib The metabolism of Olaparib can be decreased when combined with Lapatinib.Lefamulin The serum concentration of Olaparib can be increased when it is combined with Lefamulin.Leflunomide The risk or severity of adverse effects can be increased when Olaparib is combined with Leflunomide.Lemborexant The metabolism of Olaparib can be decreased when combined with Lemborexant.Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Olaparib.Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.Lercanidipine The metabolism of Olaparib can be decreased when combined with Lercanidipine.Lesinurad The metabolism of Olaparib can be increased when combined with Lesinurad.Letermovir The metabolism of Olaparib can be decreased when combined with Letermovir.Levacetylmet The metabolism of Levacetylmethadol can be decreased when combined with Olaparib.Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Olaparib.Levobupivacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Levobupivacaine.Levoketoconazole The metabolism of Olaparib can be decreased when combined with Levoketoconazole.Levonorgestrel The metabolism of Olaparib can be decreased when combined with Levonorgestrel.Lidocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Lidocaine.Linagliptin The metabolism of Olaparib can be decreased when combined with Linagliptin.Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Olaparib.Lipegfilgrastim Olaparib may increase the myelosuppressive activities of Lipegfilgrastim.Lomitapide The metabolism of Lomitapide can be decreased when combined with Olaparib.Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Olaparib.Lonafarnib The metabolism of Olaparib can be decreased when combined with Lonafarnib.Lopinavir The metabolism of Olaparib can be decreased when combined with Lopinavir.Lorlatinib The metabolism of Olaparib can be increased when combined with Lorlatinib.Losartan The metabolism of Olaparib can be decreased when combined with Losartan.Lovastatin The metabolism of Olaparib can be decreased when combined with Lovastatin.Lumacaftor The metabolism of Olaparib can be increased when combined with Lumacaftor.Magnesium The serum concentration of Magnesium can be decreased when it is combined with Olaparib.Manidipine The metabolism of Olaparib can be decreased when combined with Manidipine.Mavacamten The serum concentration of Olaparib can be decreased when it is combined with Mavacamten.Measles virus The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Olaparib.Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Olaparib.Medroxyprog The metabolism of Olaparib can be increased when combined with Medroxyprogesterone acetate.Meloxicam The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Meloxicam.Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Olaparib.Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Olaparib.Meperidine The metabolism of Olaparib can be decreased when combined with Meperidine.Mepivacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Mepivacaine.Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Olaparib.Meprednisone The metabolism of Olaparib can be increased when combined with Meprednisone.Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Olaparib.Metamizole The risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib.Methadone The metabolism of Olaparib can be decreased when combined with Methadone.Methimazole The metabolism of Olaparib can be decreased when combined with Methimazole.Methotrexate The metabolism of Methotrexate can be decreased when combined with Olaparib.Methoxy polye The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Olaparib.Methylene blue The metabolism of Olaparib can be decreased when combined with Methylene blue.Methylergometrine The metabolism of Olaparib can be decreased when combined with Methylergometrine.Methylphenobarbital The metabolism of Olaparib can be increased when combined with Methylphenobarbital.Methylprednisolone The metabolism of Olaparib can be increased when combined with Methylprednisolone.Methylprednisone The metabolism of Olaparib can be decreased when combined with Methylprednisone.Methysergide The metabolism of Olaparib can be decreased when combined with Methysergide.Metreleptin The metabolism of Olaparib can be increased when combined with Metreleptin.Metronidazole The metabolism of Olaparib can be decreased when combined with Metronidazole.Metyrapone The metabolism of Olaparib can be increased when combined with Metyrapone.Miconazole The metabolism of Olaparib can be decreased when combined with Miconazole.Midazolam The serum concentration of Midazolam can be increased when it is combined with Olaparib.Midostaurin The metabolism of Olaparib can be increased when combined with Midostaurin.Mifepristone The metabolism of Olaparib can be increased when combined with Mifepristone.Milnacipran The metabolism of Olaparib can be decreased when combined with Milnacipran.Miocamycin The metabolism of Olaparib can be decreased when combined with Miocamycin.Mirtazapine The metabolism of Olaparib can be decreased when combined with Mirtazapine.Mitapivat The metabolism of Olaparib can be increased when combined with Mitapivat.Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Olaparib.Mitotane The metabolism of Olaparib can be increased when combined with Mitotane.Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Olaparib.Mobocertinib The serum concentration of Olaparib can be decreased when it is combined with Mobocertinib.Modafinil The metabolism of Olaparib can be increased when combined with Modafinil.Moderna COVID The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Olaparib.Modified vaccinia The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Olaparib.Mometasone fur The metabolism of Olaparib can be increased when combined with Mometasone furoate.Monomethyl fum The risk or severity of adverse effects can be increased when Olaparib is combined with Monomethyl fumarate.Mosunetuzumab The metabolism of Olaparib can be decreased when combined with Mosunetuzumab.Mumps virus The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Olaparib.Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Olaparib.Mycophenolate mo The metabolism of Olaparib can be decreased when combined with Mycophenolate mofetil.Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Olaparib.Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Olaparib.Nafcillin The metabolism of Olaparib can be increased when combined with Nafcillin.Natalizumab The risk or severity of adverse effects can be increased when Olaparib is combined with Natalizumab.Nateglinide The metabolism of Olaparib can be decreased when combined with Nateglinide.Nefazodone The metabolism of Olaparib can be decreased when combined with Nefazodone.Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Olaparib.Nelfinavir The metabolism of Olaparib can be decreased when combined with Nelfinavir.Neratinib The metabolism of Neratinib can be decreased when combined with Olaparib.Netupitant The metabolism of Olaparib can be decreased when combined with Netupitant.Nevirapine The metabolism of Olaparib can be decreased when combined with Nevirapine.Niacin The metabolism of Olaparib can be decreased when combined with Niacin.Nicardipine The metabolism of Olaparib can be decreased when combined with Nicardipine.Nifedipine The metabolism of Olaparib can be decreased when combined with Nifedipine.Nilotinib The metabolism of Olaparib can be decreased when combined with Nilotinib.Nilvadipine The metabolism of Olaparib can be decreased when combined with Nilvadipine.Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Olaparib.Nintedanib The metabolism of Olaparib can be decreased when combined with Nintedanib.Nisoldipine The metabolism of Olaparib can be decreased when combined with Nisoldipine.Nitrendipine The metabolism of Olaparib can be decreased when combined with Nitrendipine.Norethisterone The metabolism of Olaparib can be decreased when combined with Norethisterone.Norgestimate The metabolism of Olaparib can be increased when combined with Norgestimate.Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Olaparib.Noscapine The metabolism of Olaparib can be decreased when combined with Noscapine.Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Olaparib.Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Olaparib.Ocrelizumab The risk or severity of adverse effects can be increased when Olaparib is combined with Ocrelizumab.Octreotide The serum concentration of Olaparib can be increased when it is combined with Octreotide.Ofatumumab The risk or severity of adverse effects can be increased when Ofatumumab is combined with Olaparib.Ondansetron The metabolism of Olaparib can be decreased when combined with Ondansetron.Oritavancin The metabolism of Olaparib can be increased when combined with Oritavancin.Orphenadrine The metabolism of Olaparib can be decreased when combined with Orphenadrine.Osilodrostat The metabolism of Olaparib can be decreased when combined with Osilodrostat.Osimertinib The metabolism of Osimertinib can be decreased when combined with Olaparib.Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Olaparib.Oxcarbazepine The metabolism of Olaparib can be increased when combined with Oxcarbazepine.Oxetacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Oxetacaine.Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Oxybuprocaine.Oxybutynin The metabolism of Olaparib can be decreased when combined with Oxybutynin.Oxycodone The metabolism of Olaparib can be decreased when combined with Oxycodone.Ozanimod The risk or severity of adverse effects can be increased when Olaparib is combined with Ozanimod.Paclitaxel The metabolism of Olaparib can be increased when combined with Paclitaxel.Pacritinib The serum concentration of Olaparib can be increased when it is combined with Pacritinib.Palbociclib The metabolism of Olaparib can be decreased when combined with Palbociclib.Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Olaparib.Paliperidone The metabolism of Olaparib can be decreased when combined with Paliperidone.Panobinostat The metabolism of Panobinostat can be decreased when combined with Olaparib.Paritaprevir The metabolism of Olaparib can be decreased when combined with Paritaprevir.Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Olaparib.Pasireotide The metabolism of Olaparib can be decreased when combined with Pasireotide.Pazopanib The metabolism of Olaparib can be decreased when combined with Pazopanib.Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Olaparib.Pegcetacoplan The risk or severity of adverse effects can be increased when Olaparib is combined with Pegcetacoplan.Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Olaparib.Peginterferon alf The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Olaparib.Peginterferon a The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Olaparib.Peginterferon The risk or severity of adverse effects can be increased when Olaparib is combined with Peginterferon beta-1a.Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Olaparib.Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Olaparib.Pentamidine The metabolism of Olaparib can be decreased when combined with Pentamidine.Pentobarbital The metabolism of Olaparib can be increased when combined with Pentobarbital.Pentosan polysu The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Olaparib.Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Olaparib.Pentoxifylline The risk or severity of bleeding can be increased when Pentoxifylline is combined with Olaparib.Perampanel The metabolism of Olaparib can be increased when combined with Perampanel.Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Olaparib.Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Olaparib.Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Olaparib.Phenobarbital The metabolism of Olaparib can be increased when combined with Phenobarbital.Phenol The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Phenol.Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Olaparib.Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Olaparib.Phenylbutazone The metabolism of Olaparib can be increased when combined with Phenylbutazone.Phenytoin The metabolism of Olaparib can be increased when combined with Phenytoin.Pimavanserin The metabolism of Olaparib can be decreased when combined with Pimavanserin.Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olaparib.Pimozide The metabolism of Pimozide can be decreased when combined with Olaparib.Piperaquine The metabolism of Olaparib can be decreased when combined with Piperaquine.Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Olaparib.Pirtobrutinib The metabolism of Olaparib can be decreased when combined with Pirtobrutinib.Pitolisant The serum concentration of Olaparib can be decreased when it is combined with Pitolisant.Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Olaparib.Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Olaparib.Ponatinib The metabolism of Ponatinib can be decreased when combined with Olaparib.Ponesimod The metabolism of Olaparib can be decreased when combined with Ponesimod.Posaconazole The metabolism of Olaparib can be decreased when combined with Posaconazole.Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Olaparib.Pralsetinib The metabolism of Olaparib can be increased when combined with Pralsetinib.Pramocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Pramocaine.Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Olaparib.Praziquantel The metabolism of Olaparib can be decreased when combined with Praziquantel.Prednisolone The metabolism of Olaparib can be increased when combined with Prednisolone.Prednisolone ac The metabolism of Olaparib can be increased when combined with Prednisolone acetate.Prednisolone phosphate The metabolism of Olaparib can be increased when combined with Prednisolone phosphate.Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Olaparib.Prednisone ace The metabolism of Olaparib can be increased when combined with Prednisone acetate.Pretomanid The metabolism of Olaparib can be decreased when combined with Pretomanid.Prilocaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Prilocaine.Primaquine The metabolism of Olaparib can be decreased when combined with Primaquine.Primidone The metabolism of Olaparib can be increased when combined with Primidone.Probenecid The metabolism of Olaparib can be increased when combined with Probenecid.Procaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Procaine.Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Olaparib.Progesterone The metabolism of Olaparib can be decreased when combined with Progesterone.Proparacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Proparacaine.Propofol The metabolism of Olaparib can be decreased when combined with Propofol.Propoxycaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Propoxycaine.Propranolol The metabolism of Olaparib can be decreased when combined with Propranolol.Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Olaparib.Protein C The risk or severity of bleeding can be increased when Protein C is combined with Olaparib.Protein S human The risk or severity of bleeding can be increased when Protein S human is combined with Olaparib.Prucalopride The metabolism of Prucalopride can be decreased when combined with Olaparib.Quetiapine The metabolism of Olaparib can be decreased when combined with Quetiapine.Quinidine The metabolism of Olaparib can be decreased when combined with Quinidine.Quinine The metabolism of Olaparib can be increased when combined with Quinine.Quinupristin The metabolism of Olaparib can be decreased when combined with Quinupristin.Rabies immune The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Olaparib.Rabie antigen, A The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Olaparib.Rabie antigen, B The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Olaparib.Raloxifene The metabolism of Olaparib can be decreased when combined with Raloxifene.Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Olaparib.Ranolazine The metabolism of Olaparib can be decreased when combined with Ranolazine.Ravulizumab The risk or severity of adverse effects can be increased when Olaparib is combined with Ravulizumab.Regorafenib The metabolism of Regorafenib can be decreased when combined with Olaparib.Relugolix The metabolism of Olaparib can be decreased when combined with Relugolix.Remdesivir The metabolism of Olaparib can be decreased when combined with Remdesivir.Reserpine The metabolism of Olaparib can be increased when combined with Reserpine.Retapamulin The metabolism of Retapamulin can be decreased when combined with Olaparib.Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Olaparib.Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Olaparib.Ribociclib The metabolism of Olaparib can be decreased when combined with Ribociclib.Rifabutin The metabolism of Olaparib can be increased when combined with Rifabutin.Rifampicin The metabolism of Olaparib can be increased when combined with Rifampicin.Rifamycin The metabolism of Olaparib can be increased when combined with Rifamycin.Rifapentine The metabolism of Olaparib can be increased when combined with Rifapentine.Rilonacept The metabolism of Olaparib can be increased when combined with Rilonacept.Rilpivirine The metabolism of Olaparib can be decreased when combined with Rilpivirine.Rimexolone The metabolism of Olaparib can be increased when combined with Rimexolone.Risankizumab The risk or severity of adverse effects can be increased when Olaparib is combined with Risankizumab.Risperidone The metabolism of Olaparib can be decreased when combined with Risperidone.Ritonavir The metabolism of Olaparib can be decreased when combined with Ritonavir.Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Olaparib.Rivaroxaban The metabolism of Olaparib can be decreased when combined with Rivaroxaban.Rofecoxib The metabolism of Olaparib can be increased when combined with Rofecoxib.Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Olaparib.Romidepsin The metabolism of Romidepsin can be decreased when combined with Olaparib.Ropeginterfe The risk or severity of adverse effects can be increased when Olaparib is combined with Ropeginterferon alfa-2b.Ropivacaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Ropivacaine.Rosuvastatin The metabolism of Olaparib can be decreased when combined with Rosuvastatin.Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Olaparib.Roxithromycin The metabolism of Olaparib can be decreased when combined with Roxithromycin.Rubella virus va The risk or severity of infection can be increased when Rubella virus vaccine is combined with Olaparib.Rucaparib The metabolism of Olaparib can be decreased when combined with Rucaparib.Rufinamide The metabolism of Olaparib can be increased when combined with Rufinamide.Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Olaparib.Salmeterol The metabolism of Olaparib can be decreased when combined with Salmeterol.Saquinavir The metabolism of Olaparib can be decreased when combined with Saquinavir.Sarilumab The metabolism of Olaparib can be increased when combined with Sarilumab.Satralizumab The serum concentration of Olaparib can be decreased when it is combined with Satralizumab.Saxagliptin The metabolism of Olaparib can be decreased when combined with Saxagliptin.Secobarbital The metabolism of Olaparib can be increased when combined with Secobarbital.Secukinumab The metabolism of Olaparib can be increased when combined with Secukinumab.Selumetinib The metabolism of Olaparib can be decreased when combined with Selumetinib.Sildenafil The metabolism of Olaparib can be decreased when combined with Sildenafil.Siltuximab The metabolism of Olaparib can be increased when combined with Siltuximab.Simeprevir The metabolism of Olaparib can be decreased when combined with Simeprevir.Simvastatin The metabolism of Olaparib can be decreased when combined with Simvastatin.Siponimod The metabolism of Siponimod can be decreased when combined with Olaparib.Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Olaparib.Sirolimus The metabolism of Sirolimus can be decreased when combined with Olaparib.Sitaxentan The metabolism of Olaparib can be decreased when combined with Sitaxentan.Smallpox (Vaccini The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Olaparib.Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Olaparib.Somatostatin The metabolism of Olaparib can be decreased when combined with Somatostatin.Somatrogon The metabolism of Olaparib can be increased when combined with Somatrogon.Sonidegib The metabolism of Sonidegib can be decreased when combined with Olaparib.Sorafenib The metabolism of Sorafenib can be decreased when combined with Olaparib.Sotorasib The serum concentration of Olaparib can be decreased when it is combined with Sotorasib.Spesolimab The risk or severity of adverse effects can be increased when Olaparib is combined with Spesolimab.St. John's Wort The metabolism of Olaparib can be increased when combined with St. John's Wort.Stiripentol The metabolism of Olaparib can be decreased when combined with Stiripentol.Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Olaparib.Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Olaparib.Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Olaparib.Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Olaparib.Sulfinpyrazone The metabolism of Olaparib can be increased when combined with Sulfinpyrazone.Sulodexide The risk or severity of bleeding can be increased when Sulodexide is combined with Olaparib.Sunitinib The metabolism of Sunitinib can be decreased when combined with Olaparib.Sutimlimab The risk or severity of adverse effects can be increased when Olaparib is combined with Sutimlimab.Suvorexant The metabolism of Olaparib can be decreased when combined with Suvorexant.Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Olaparib.Tadalafil The metabolism of Olaparib can be decreased when combined with Tadalafil.Tamoxifen The metabolism of Olaparib can be increased when combined with Tamoxifen.Tasimelteon The metabolism of Olaparib can be decreased when combined with Tasimelteon.Tazemetostat The metabolism of Olaparib can be decreased when combined with Tazemetostat.Tecovirimat The metabolism of Olaparib can be increased when combined with Tecovirimat.Tedizolid phosp The risk or severity of myelosuppression can be increased when Tedizolid phosphate is combined with Olaparib.Tegafur The metabolism of Tegafur can be decreased when combined with Olaparib.Telaprevir The metabolism of Olaparib can be decreased when combined with Telaprevir.Telithromycin The metabolism of Olaparib can be decreased when combined with Telithromycin.Telotristat ethyl The serum concentration of Olaparib can be decreased when it is combined with Telotristat ethyl.Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Olaparib.Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Olaparib.Tenecteplase The risk or severity of bleeding can be increased when Tenecteplase is combined with Olaparib.Teniposide The metabolism of Teniposide can be decreased when combined with Olaparib.Tenofovir alafe The metabolism of Olaparib can be decreased when combined with Tenofovir alafenamide.Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Olaparib.Terbinafine The metabolism of Olaparib can be increased when combined with Terbinafine.Terfenadine The metabolism of Olaparib can be decreased when combined with Terfenadine.Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Olaparib.Testosterone The metabolism of Olaparib can be increased when combined with Testosterone.Testosterone cy The metabolism of Olaparib can be decreased when combined with Testosterone cypionate.Testosterone en The metabolism of Olaparib can be decreased when combined with Testosterone enanthate.Tetracaine The risk or severity of methemoglobinemia can be increased when Olaparib is combined with Tetracaine.Tetracycline The metabolism of Olaparib can be decreased when combined with Tetracycline.Tezacaftor The metabolism of Olaparib can be decreased when combined with Tezacaftor.Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Olaparib.Theophylline The metabolism of Theophylline can be decreased when combined with Olaparib.Thiamylal The metabolism of Olaparib can be increased when combined with Thiamylal.Thiotepa The metabolism of Thiotepa can be decreased when combined with Olaparib.Ticagrelor The metabolism of Olaparib can be decreased when combined with Ticagrelor.Tick-borne encep The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Olaparib.Ticlopidine The risk or severity of bleeding can be increased when Ticlopidine is combined with Olaparib.Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Olaparib.Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Olaparib.Tipranavir The metabolism of Olaparib can be decreased when combined with Tipranavir.Tirofiban The risk or severity of bleeding can be increased when Tirofiban is combined with Olaparib.Tixocortol The risk or severity of adverse effects can be increased when Olaparib is combined with Tixocortol.Tocilizumab The metabolism of Olaparib can be increased when combined with Tocilizumab.Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Olaparib.Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Olaparib.Topiramate The metabolism of Olaparib can be increased when combined with Topiramate.Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Olaparib.Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Olaparib.Trabectedin The metabolism of Trabectedin can be decreased when combined with Olaparib.Tramadol The metabolism of Tramadol can be decreased when combined with Olaparib.Trastuzumab Trastuzumab may increase the neutropenic activities of Olaparib.Trastuzumab e The metabolism of Trastuzumab emtansine can be decreased when combined with Olaparib.Trazodone The metabolism of Olaparib can be decreased when combined with Trazodone.Tretinoin The metabolism of Olaparib can be decreased when combined with Tretinoin.Triamcinolone The metabolism of Olaparib can be increased when combined with Triamcinolone.Triazolam The metabolism of Olaparib can be decreased when combined with Triazolam.Trichlormeth The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Olaparib.Triclabendazole The metabolism of Olaparib can be decreased when combined with Triclabendazole.Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Olaparib.Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Olaparib.Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Olaparib.Troglitazone The metabolism of Olaparib can be increased when combined with Troglitazone.Troleandomycin The metabolism of Olaparib can be decreased when combined with Troleandomycin.Tucatinib The metabolism of Tucatinib can be decreased when combined with Olaparib.Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Olaparib.Typhoid Vacci The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Olaparib.Typhoid Vi pol The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Olaparib.Ublituximab The risk or severity of infection can be increased when Ublituximab is combined with Olaparib.Ubrogepant The serum concentration of Ubrogepant can be increased when it is combined with Olaparib.Udenafil The metabolism of Olaparib can be decreased when combined with Udenafil.Upadacitinib The risk or severity of adverse effects can be increased when Olaparib is combined with Upadacitinib.Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Olaparib.Valbenazine The metabolism of Olaparib can be decreased when combined with Valbenazine.Valproic acid The metabolism of Olaparib can be decreased when combined with Valproic acid.Vandetanib The metabolism of Vandetanib can be decreased when combined with Olaparib.Vardenafil The metabolism of Vardenafil can be decreased when combined with Olaparib.Varicella zoster v The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Olaparib.Varicella zoster The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Olaparib.Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Olaparib.Vemurafenib The metabolism of Olaparib can be increased when combined with Vemurafenib.Venetoclax The metabolism of Olaparib can be decreased when combined with Venetoclax.Verapamil The metabolism of Olaparib can be decreased when combined with Verapamil.Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Olaparib.Vilanterol The risk or severity of adverse effects can be increased when Olaparib is combined with Vilanterol.Viloxazine The metabolism of Olaparib can be decreased when combined with Viloxazine.Vinblastine The metabolism of Olaparib can be increased when combined with Vinblastine.Vincristine The metabolism of Vincristine can be decreased when combined with Olaparib.Vindesine The metabolism of Vindesine can be decreased when combined with Olaparib.Vinflunine The metabolism of Vinflunine can be decreased when combined with Olaparib.Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Olaparib.Vitamin E The metabolism of Olaparib can be increased when combined with Vitamin E.Voclosporin The risk or severity of adverse effects can be increased when Olaparib is combined with Voclosporin.Vonoprazan The metabolism of Olaparib can be decreased when combined with Vonoprazan.Vorapaxar The metabolism of Olaparib can be decreased when combined with Vorapaxar.Voriconazole The metabolism of Olaparib can be decreased when combined with Voriconazole.Vorinostat The risk or severity of adverse effects can be increased when Vorinostat is combined with Olaparib.Vortioxetine The metabolism of Olaparib can be decreased when combined with Vortioxetine.Voxelotor The serum concentration of Olaparib can be increased when it is combined with Voxelotor.Warfarin The serum concentration of Warfarin can be increased when it is combined with Olaparib.Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Olaparib.Yellow fever vacci The risk or severity of infection can be increased when Yellow fever vaccine is combined with Olaparib.Zafirlukast The metabolism of Olaparib can be decreased when combined with Zafirlukast.Zaleplon The metabolism of Olaparib can be decreased when combined with Zaleplon.Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Olaparib.Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Olaparib.Zimelidine The metabolism of Olaparib can be decreased when combined with Zimelidine.Ziprasidone The metabolism of Olaparib can be decreased when combined with Ziprasidone.Zonisamide The metabolism of Olaparib can be decreased when combined with Zonisamide.Zopiclone The metabolism of Zopiclone can be decreased when combined with Olaparib.Zuclopenthixol The metabolism of Olaparib can be decreased when combined with Zuclopenthixol.Pregnancy and LactationAU TGA pregnancy category: D US FDA pregnancy category: Not assigned.Pregnancy Based on findings in animals and its mechanism of action [see Clinical Pharmacology (12.1)], Lynparza can cause fetal harm when administered to a pregnant woman. There are no available data on Lynparza use in pregnant women to inform the drug-associated risk. In an animal reproduction study, the administration of olaparib to pregnant rats during the period of organogenesis caused teratogenicity and embryo-fetal toxicity at exposures below those in patients receiving the recommended human dose of 300 mg twice daily [see Data]. Apprise pregnant women of the potential hazard to the fetus and the potential risk for loss of the pregnancy. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. The estimated background risk in the U.S. general population of major birth defects is 2-4%; and the risk for spontaneous abortion is approximately 15-20% in clinically recognized pregnancies. Lactation No information is available on the clinical use of olaparib during breastfeeding. Because olaparib is 82% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during olaparib therapy and for one month after the last dose.Why is this medication prescribed?

Olaparib is used alone or in combination with bevacizumab (Avastin) to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Olaparib is also used to treat certain types of breast cancer that has spread…

How should this medicine be used?

Olaparib comes as a tablet to take by mouth twice daily with or without food. Try to space your doses about 12 hours apart. Take olaparib at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take olaparib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor. Swallow the…

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area later with a custom field named _rx_references.

Related Articles

Vasodilator Drugs

June 9, 20258 min read5 views

Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   Vasodilators are medicines…

Read more

Written by Dr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Dr. Md. Harun Ar Rashid, MPH, MD, PhD, is a highly respected medical specialist celebrated for his exceptional clinical expertise and unwavering commitment to patient care. With advanced qualifications including MPH, MD, and PhD, he integrates cutting-edge research with a compassionate approach to medicine, ensuring that every patient receives personalized and effective treatment. His extensive training and hands-on experience enable him to diagnose complex conditions accurately and develop innovative treatment strategies tailored to individual needs. In addition to his clinical practice, Dr. Harun Ar Rashid is dedicated to medical education and research, writing and inventory creative thinking, innovative idea, critical care managementing make in his community to outreach, often participating in initiatives that promote health awareness and advance medical knowledge. His career is a testament to the high standards represented by his credentials, and he continues to contribute significantly to his field, driving improvements in both patient outcomes and healthcare practices. Born and educated in Bangladesh, Dr. Rashid earned his BPT from the University of Dhaka before pursuing postgraduate training internationally. He completed his MD in Internal Medicine at King’s College London, where he developed a special interest in inflammatory arthritis and metabolic bone disease. He then undertook a PhD in Orthopedic Science at the University of Oxford, conducting pioneering research on cytokine signaling pathways in rheumatoid arthritis. Following his doctoral studies, Dr. Rashid returned to clinical work with a fellowship in interventional pain management at the Rx University School of Medicine, refining his skills in image-guided joint injections and minimally invasive pain-relief techniques.